Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin

Biochemical and Biophysical Research Communications

Volumn 407, Issue 1, 2011, Pages 103-107

  Schoppet, Michael ^a   Kavurma, Mary M ^b   Hofbauer, Lorenz C ^c   Shanahan, Catherine M ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Nanoparticles; Osteoprotegerin; Vascular calcification; Vascular smooth muscle cells

Indexed keywords

CALCIUM; CALPHOBINDIN II; MESSENGER RNA; MINERAL; NANOPARTICLE; OSTEOPROTEGERIN; PHOSPHATE; PHOSPHOLIPID BINDING PROTEIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; BONE; BONE MINERALIZATION; CELL VACUOLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYSTALLIZATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MATRIX VESICLE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

CALCIFICATION, PHYSIOLOGIC; CALCINOSIS; CALCIUM; CRYSTALLIZATION; HUMANS; MICROSCOPY, CONFOCAL; MUSCLE, SMOOTH; MUSCLE, SMOOTH, VASCULAR; NANOPARTICLES; OSTEOPROTEGERIN; PHOSPHORUS; PLAQUE, ATHEROSCLEROTIC;

RODENTIA;

EID: 79953160859     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.02.117     Document Type: Article

References (25)

1. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 2924:490-495.
2. Bucay N., Sarosi I., Dunstan C.R., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
3. Panizo S., Cardus A., Encinas M., et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 2009, 104:1041-1048.
4. Osako M.K., Nakagami H., Koibuchi N., et al. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 2010, 107:466-475.
5. Price P.A., June H.H., Buckley J.R., et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1610-1616.
6. (-/-) mice. Circulation 2008, 117:411-420.
7. -/- mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2117-2124.
8. Schoppet M., Sattler A.M., Schaefer J.R., et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J. Clin. Endocrinol. Metab. 2003, 88:1024-1028.
9. Jono S., Ikari Y., Shioi A., et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 2002, 106:1192-1194.
10. Kiechl S., Schett G., Wenning G., et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004, 109:2175-2180.
11. Kazama J.J., Shigematsu T., Yano K., et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am. J. Kidney Dis. 2002, 39:525-532.
12. Candido R., Toffoli B., Corallini F., et al. Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J. Vasc. Res. 2010, 47:252-261.
13. Wittrant Y., Couillaud S., Theoleyre S., et al. Osteoprotegerin differentially regulates protease expression in osteoclast cultures. Biochem. Biophys. Res. Commun. 2002, 293:38-44.
14. Reynolds J.L., Joannides A.J., Skepper J.N., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 2004, 15:2857-2867.
15. Delafontaine P., Song Y.H., Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 2004, 24:435-444.
16. Wuthier R.E., Chin J.E., Hale J.E., et al. Isolation and characterization of calcium-accumulating matrix vesicles from chondrocytes of chicken epiphyseal growth plate cartilage in primary culture. J. Biol. Chem. 1985, 260:15972-15979.
17. Hashimoto S., Ochs R.L., Rosen F., et al. Chondrocyte-derived apoptotic bodies and calcification of articular cartilage. Proc. Natl. Acad. Sci. USA 1998, 95:3094-3099.
18. Yamaguchi K., Kinosaki M., Goto M., et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J. Biol. Chem. 1998, 273:5117-5123.
19. Lee D.W., Zhao X., Scarselletta S., et al. ATP binding regulates oligomerization and endosome association of RME-1 family proteins. J. Biol. Chem. 2005, 280:17213-17220.
20. Schoppet M., Al-Fakhri N., Franke F.E., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J. Clin. Endocrinol. Metab. 2004, 89:4104-4112.
21. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 2004, 95:1046-1057.
22. Silvestrini G., Ballanti P., Patacchioli F., et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J. Mol. Histol. 2005, 36:59-67.
23. Shroff R.C., Shanahan C.M. The vascular biology of calcification. Semin. Dial. 2007, 20:103-109.
24. Reynolds J.L., Skepper J.N., McNair R., et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J. Am. Soc. Nephrol. 2005, 16:2920-2930.
25. Proudfoot D., Skepper J.N., Hegyi L., et al. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ. Res. 2000, 87:1055-1062.